- Home
- HRTX vs CAPR Comparison
HRTX vs CAPR Comparison
Compare HRTX & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRTX
- CAPR
- Stock Information
- Founded
- HRTX 1983
- CAPR 2005
- Country
- HRTX United States
- CAPR United States
- Employees
- HRTX N/A
- CAPR N/A
- Industry
- HRTX Biotechnology: Pharmaceutical Preparations
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HRTX Health Care
- CAPR Health Care
- Exchange
- HRTX Nasdaq
- CAPR Nasdaq
- Market Cap
- HRTX 276.1M
- CAPR 324.6M
- IPO Year
- HRTX 1987
- CAPR N/A
- Fundamental
- Price
- HRTX $1.35
- CAPR $6.28
- Analyst Decision
- HRTX Strong Buy
- CAPR Strong Buy
- Analyst Count
- HRTX 2
- CAPR 8
- Target Price
- HRTX $4.50
- CAPR $24.75
- AVG Volume (30 Days)
- HRTX 2.6M
- CAPR 1.4M
- Earning Date
- HRTX 08-08-2025
- CAPR 08-11-2025
- Dividend Yield
- HRTX N/A
- CAPR N/A
- EPS Growth
- HRTX N/A
- CAPR N/A
- EPS
- HRTX N/A
- CAPR N/A
- Revenue
- HRTX $149,694,000.00
- CAPR $13,392,150.00
- Revenue This Year
- HRTX $10.62
- CAPR N/A
- Revenue Next Year
- HRTX $12.99
- CAPR $6,061.53
- P/E Ratio
- HRTX N/A
- CAPR N/A
- Revenue Growth
- HRTX 9.78
- CAPR N/A
- 52 Week Low
- HRTX $1.04
- CAPR $3.98
- 52 Week High
- HRTX $2.68
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- HRTX 36.48
- CAPR 36.33
- Support Level
- HRTX $1.33
- CAPR $6.17
- Resistance Level
- HRTX $1.43
- CAPR $7.30
- Average True Range (ATR)
- HRTX 0.07
- CAPR 0.43
- MACD
- HRTX 0.02
- CAPR -0.11
- Stochastic Oscillator
- HRTX 45.45
- CAPR 4.53
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.